Synta Pharmaceuticals Corp. Company Profile (NASDAQ:SNTA)

Analyst Ratings

Consensus Ratings for Synta Pharmaceuticals Corp. (NASDAQ:SNTA) (?)
Ratings Breakdown: 4 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $3.17 (823.23% upside)

Analysts' Ratings History for Synta Pharmaceuticals Corp. (NASDAQ:SNTA)
Show:
DateFirmActionRatingPrice TargetActions
10/21/2015JMP SecuritiesDowngradeMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/21/2015Cowen and CompanyDowngradeOutperform -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/21/2015FBR & CoDowngradeOutperform -> Market Perform$2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/21/2015Roth CapitalDowngradeBuy -> Neutral$13.00 -> $1.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/10/2015MLV & Co.Reiterated RatingBuy$6.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/10/2015Canaccord GenuityInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Synta Pharmaceuticals Corp. (NASDAQ:SNTA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
3/10/2016        
3/15/2016Q4($0.18)($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q3($0.16)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.18)($0.15)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.19)($0.19)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q4($0.21)($0.19)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q3($0.24)($0.19)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q2($0.27)($0.24)$480.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q1($0.29)($0.28)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2014Q4($0.30)($0.31)$0.37 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2013Q313($0.31)($0.33)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013($0.30)($0.33)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2012Q312($0.24)($0.25)$1.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Synta Pharmaceuticals Corp. (NASDAQ:SNTA)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Synta Pharmaceuticals Corp. (NASDAQ:SNTA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Synta Pharmaceuticals Corp. (NASDAQ:SNTA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/14/2015Keith R GollustDirectorSell600,000$0.35$210,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2015Keith R GollustDirectorSell745,892$0.38$283,438.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2015Bruce KovnerDirectorSell1,523,346$0.37$563,638.02View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015Bruce KovnerDirectorSell1,430,753$0.43$615,223.79View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/30/2015Bruce KovnerDirectorSell3,078,820$0.48$1,477,833.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Bruce KovnerDirectorSell1,173,582$0.44$516,376.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2015Bruce KovnerDirectorSell1,513,088$0.49$741,413.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015Bruce KovnerDirectorSell1,223,936$0.43$526,292.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2015Bruce KovnerDirectorSell5,436,673$0.55$2,990,170.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2015Keith R GollustDirectorSell188,322$0.55$103,577.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2015Robert N WilsonDirectorBuy50,000$1.75$87,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2014Bruce KovnerDirectorBuy300,000$3.08$924,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/11/2014Bruce KovnerDirectorBuy1,250,000$4.01$5,012,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2013Bruce KovnerDirectorBuy5,000,000$3.75$18,750,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2013Safi BahcallCEOBuy20,000$3.75$75,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/28/2013Safi R BahcallCEOBuy10,000$5.03$50,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/27/2013Bruce KovnerDirectorBuy150,000$4.71$706,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2013Bruce KovnerDirectorBuy500,000$4.53$2,265,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/21/2013Bruce KovnerDirectorBuy250,000$4.39$1,097,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/21/2013Safi R BahcallCEOBuy20,000$4.12$82,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2013Bruce KovnerDirectorBuy200,000$4.00$800,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2013Safi R BahcallCEOBuy10,000$4.06$40,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2013Bruce KovnerDirectorBuy2,000,000$4.64$9,280,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2013Safi R BahcallCEOBuy10,000$4.04$40,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2013Vojo VukovicSVPBuy10,000$4.58$45,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2013Robert N WilsonDirectorBuy10,000$5.00$50,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2012Bruce KovnerDirectorBuy37,700$6.91$260,507.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2012Safi R BahcallCEOBuy10,000$7.12$71,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Synta Pharmaceuticals Corp. (NASDAQ:SNTA)
DateHeadline
07/25/16 06:40 PMStocks on the Move: Synta Pharmaceuticals Corp. (SNTA), Honeywell International Inc. (HON), United States Steel ... - iStreetWire
07/25/16 06:40 PMHealthcare Stocks in Hot Folio- Valeant Pharmaceuticals International (NYSE:VRX), Synta Pharmaceuticals (NASDAQ ... - Seneca Globe
07/25/16 06:40 PMNotable Stock Broker Reports on Synta Pharmaceuticals Corp. (NASDAQ:SNTA) - The Voice Registrar
07/23/16 05:53 PMSynta Pharmaceuticals Corporation: Madrigal Pharmaceuticals Completes Merger ...
07/23/16 05:53 PMSynta Pharmaceuticals Corp. (SNTA) Jumps 26.62% on July 22
07/23/16 10:34 AM11:34 am Synta Pharma completes merger with Madrigal Pharmaceuticals, conducts 1:35 reverse split; combined company to be named Madrigal Pharmaceuticals and begin trading under symbol MDGL on July 25 -
07/23/16 10:17 AMStock Up Nicely This Week: Synta Pharmaceuticals Corp. (NASDAQ:SNTA) - TGP
07/23/16 10:17 AMSynta Pharmaceuticals Corp. (SNTA) Jumps 26.62% on July 22 - Equities.com
07/22/16 06:18 PMStock Update: Tracking Unusual Volume for Synta Pharmaceuticals Corp. (NASDAQ:SNTA) - Engelwood Daily
07/22/16 04:02 PMSYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Unregistered Sale -
07/22/16 11:18 AMMadrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company - [at noodls] - FORT WASHINGTON, Pa., July 22, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative ...
07/22/16 09:24 AMSynta Pharmaceuticals Incorporated (NASDAQ:SNTA) Sellers Covered 52.63% of Their Shorts - Consumer Eagle
07/20/16 07:27 PMSynta Pharmaceuticals Corp. Stock Technicals at Critical Inflection Point - CML News
07/20/16 07:27 PMStock Moving Lower for the Month; Investor Update on Synta Pharmaceuticals Corp. (NASDAQ:SNTA) - Engelwood Daily
07/20/16 03:04 PMSYNTA PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report -
07/19/16 07:16 AMSynta Pharmaceuticals Incorporated (NASDAQ:SNTA) Shorted Shares Decreased By 4.24% - Consumer Eagle
07/18/16 11:18 AMNext Weeks Broker Price Targets For Synta Pharmaceuticals Corp. (SNTA) - Fiscal Standard
07/12/16 06:43 PMSynta Pharmaceuticals Corp. (SNTA) Drops 5.01% on July 11 - Equities.com
07/09/16 05:49 PMHow Many Synta Pharmaceuticals Corp. (NASDAQ:SNTA)'s Analysts Are Bearish? - Press Telegraph
07/08/16 09:21 AMSynta Pharmaceuticals Incorporated (NASDAQ:SNTA) Shorts Decreased by 4.24% After Short Covering - Engelwood Daily
07/08/16 09:21 AMSynta Pharmaceuticals Corp. (SNTA) Current Analyst Ratings - Fiscal Standard
07/03/16 10:35 AMCompany Stock Lower on the Week Synta Pharmaceuticals Corp. (NASDAQ:SNTA) - Engelwood Daily
07/02/16 09:06 AMSynta Pharmaceuticals Incorporated (NASDAQ:SNTA) Shorted Shares Decreased By 4.24% - Engelwood Daily
07/01/16 09:11 AMWhy Investors Have These Biotech Stocks on Their Radar? - Synta Pharma, Idera Pharma, Threshold Pharma, and Viking Therapeutics
06/27/16 10:34 AMAnalysts watching two Stocks: Gilead Sciences, Inc. (NASDAQ:GILD) , Synta Pharmaceuticals Corp. (NASDAQ:SNTA) - Street Updates
06/27/16 10:34 AMHC Stocks Indications: Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) - share market updates (press release)
06/24/16 09:04 AMStock on the Move: Synta Pharmaceuticals Corp. (UTC:SNTA) - iStreetWire
06/22/16 11:07 AMSynta Pharmaceuticals To Present At JMP Securities Conference;Webcast At 12:00PM
06/18/16 05:36 PMSynta Pharmaceuticals Corp. (SNTA) Jumps 6.78% on June 17 - Equities.com
06/18/16 10:33 AMSynta Pharmaceuticals Corp. (SNTA) Jumps 6.78% on June 17
06/16/16 06:42 PMBig Movers: Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Civista Bancshares, Inc. (NASDAQ:CIVB), Advanced Micro ... - KC Register
06/16/16 06:42 PMSynta Pharmaceuticals Corp. (SNTA) Drops 7.54% on June 14 - Equities.com
06/16/16 10:54 AMSynta Pharmaceuticals Corp. (SNTA) Drops 7.54% on June 14
06/09/16 06:58 PMGoldberg Law PC (http://www Goldberglawpc com) announces that it is investigating claims of potential misrepresentations by Neovasc, Inc
06/09/16 06:58 PMSynta Announces Date and Location of Annual Meeting of Stockholders to Vote on Merger with Madrigal Pharmaceuticals
06/08/16 07:00 PMSynta Pharmaceuticals Corporation: Synta Announces Date and Location of Annual Meeting of Stockholders to Vote on ... - The Wall Street Transcript
06/03/16 04:16 PMSYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events -
06/02/16 09:41 AMSynta Pharmaceuticals to Present at Upcoming Investor Conferences in June - Business Wire (press release) - Synta Pharmaceuticals to Present at Upcoming Investor Conferences in JuneBusiness Wire (press release)LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (“Synta”) (NASDAQ:SNTA) today announced that Marc Schneebaum, Chief Financial Officer of Synta, will be joined by Paul Friedman, M.D., designated Chairman and Chief Executive ...and more »
06/02/16 06:15 AMSynta Pharmaceuticals to Present at Upcoming Investor Conferences in June - [at noodls] - LEXINGTON, Mass.--(BUSINESS WIRE)--Jun. 2, 2016-- Synta Pharmaceuticals Corp. ('Synta') (NASDAQ:SNTA) today announced that Marc Schneebaum, Chief Financial Officer of Synta, will be joined by Paul Friedman, ...
05/31/16 06:53 PMSynta Pharmaceuticals Corp. (NASDAQ:SNTA) increased 0.25%: Galapagos NV (NASDAQ:GLPG), CNA Financial ... - KC Register - Synta Pharmaceuticals Corp. (NASDAQ:SNTA) increased 0.25%: Galapagos NV (NASDAQ:GLPG), CNA Financial ...KC RegisterOn Friday Synta Pharmaceuticals Corp. (NASDAQ:SNTA) share price closed at $0.36. Company return on equity (ROE) is -97.30%. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) is -5.71% away from its 52 week high and its 52 week range is $0.1500 ...
05/30/16 10:18 PMSynta Pharmaceuticals Corp. (SNTA) Broker Price Targets For The Coming Week - Share Trading News - Synta Pharmaceuticals Corp. (SNTA) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Synta Pharmaceuticals Corp. (SNTA). The latest reports which are currently in issue on Monday 30th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy ...Synta Pharmaceuticals Incorporated (NASDAQ:SNTA) Sellers Increased By 9.63% Their ShortsHNNall 2 news articles »
05/27/16 10:55 PMSynta Pharmaceuticals : Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics - Additionally, shares of Synta Pharmaceuticals have a Relative Strength Index (RSI) of 48.50. Sign up and get the alert on SNTA at: http://www.activewallst.com/register On Thursday, shares in biopharma Company, CTI BioPharma Corp., ended the session at $0 ...
05/27/16 10:55 PMSynta Pharmaceuticals Corp. (SNTA) Drops 5.11% on May 26 - Synta Pharmaceuticals Corp. (SNTA) was one of the Russell 2000's biggest losers for Thursday May 26 as the stock slid 5.11% to $0.36, a loss of $-0.0194 per share. Starting at an opening price of $0.37 a share, the stock traded between $0.36 and $0.39 over ...
05/27/16 05:47 PMSynta Pharmaceuticals Corp. (SNTA) Drops 5.11% on May 26 - Equities.com - Synta Pharmaceuticals Corp. (SNTA) Drops 5.11% on May 26Equities.comSynta Pharmaceuticals Corp. (SNTA) was one of the Russell 2000's biggest losers for Thursday May 26 as the stock slid 5.11% to $0.36, a loss of $-0.0194 per share. Starting at an opening price of $0.37 a share, the stock traded between $0.36 and $0.39 ...Synta Pharmaceuticals Corp. (SNTA) Analyst ReviewRisers & Fallersall 3 news articles »
05/26/16 05:37 PMSynta Pharmaceuticals Incorporated (NASDAQ:SNTA) Sellers Covered 5.44% of Their Shorts - Wall Street Hints and News - Synta Pharmaceuticals Incorporated (NASDAQ:SNTA) Sellers Covered 5.44% of Their ShortsWall Street Hints and NewsThe short interest to Synta Pharmaceuticals Incorporated's float is 5.71%. The stock increased 2.70% or $0.01 during the last trading session, hitting $0.38. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) has declined 81.37% since October 20, 2015 and is ...
05/22/16 10:06 PMAfter Last Week What Do Analysts Think Of Synta Pharmaceuticals Corp. (SNTA) - Share Trading News - After Last Week What Do Analysts Think Of Synta Pharmaceuticals Corp. (SNTA)Share Trading News10/21/2015 – Synta Pharmaceuticals Corp. had its “mkt perform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 2 price target on the stock. 10/21/2015 – Synta Pharmaceuticals Corp. was downgraded to “neutral” by analysts at ...Alpha One Assigns Impact Score Of 84 To Synta Pharmaceuticals Corp. (NASDAQ:SNTA)Investor NewswireAfter Recent Decline, is it Time to Sell Synta Pharmaceuticals Corp. (NASDAQ:SNTA)Franklin Independentall 3 news articles »
05/19/16 12:04 PMSYNTA PHARMACEUTICALS CORP Financials -
05/03/16 07:16 AMSYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
04/21/16 08:30 AMThe Zacks Analyst Blog Highlights: Medivation, Synta, AbbVie, Gilead and Orexigen -
04/15/16 10:30 AMSynta Stock Up on Merger Deal with Madrigal Pharmaceuticals -

Social

About Synta Pharmaceuticals Corp.

Synta Pharmaceuticals Corp. logoSynta Pharmaceuticals Corp. is focused on research, development and commercialization of oncology medicines. The Company's segment is the discovery, development and commercialization of drug products. It has a clinical-stage drug candidate in oncology (ganetespib), and a small molecule cancer drug development program (heat shock protein 90 (Hsp90) inhibitor Drug Conjugate (HDC) program). It is engaged in evaluating various candidates from its HDC program, which leverages the preferential accumulation of Hsp90 inhibitors in tumors to selectively deliver a range of anti-cancer payloads. Ganetespib is a small molecule inhibitor of Hsp90, a molecular chaperone that is required for the folding and activation of various cancer-promoting proteins. It is engaged in conducting preclinical studies for its clinical candidate from the HDC program, STA-12-8666. It holds interests in its drug candidate, elesclomol, and the calcium release-activated calcium modulator (CRACM) inhibitor program.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: SNTA
  • CUSIP: 87162T20
Key Metrics:
  • Previous Close: $0.34
  • 50 Day Moving Average: $0.303
  • 200 Day Moving Average: $0.290
  • P/E Ratio: N/A
  • P/E Growth: 0.000
  • Market Cap: $47.13M
  • Beta: 1.06
  • Current Year EPS Consensus Estimate: $-0.070 EPS
  • Next Year EPS Consensus Estimate: $-0.010 EPS
Additional Links:
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Chart for Monday, July, 25, 2016